NEW YORK, May 14 -
Lynx will apply its core "Massively Parallel Signature Sequencing" technology to identify genes that are differentially expressed in this cancer, and ISB will contribute other data.
The initial collaboration, begun about one year ago, led to the discovery of "numerous potential prostate cancer-specific genes," which the partners are preparing to publish.
"Because of its ability in detecting transcripts expressed at extremely low levels, MPSS technology enabled us to monitor global changes in gene expression and to start building pathways and networks perturbed in prostate cancer cells," said Biaoyang Lin, a senior scientist and project leader at ISB, in a statement.
This new agreement will include additional MPSS analysis of prostate cancer patient biopsy samples.
Lynx will be paid fees for the services it performs under the agreement, but the parties did not disclose the amount of these fees. The ISB garned funding for the continuation of the study through an award from prostate cancer research nonprofit CapCURE, Lynx said.
Prostate cancer typically progresses from a localized androgen-dependent disease to a more dangerous metastatic form, but the biological details of this transformation are not well understood. The systems biology approach, according to Lynx, may provide new insights into the mechanisms of this disease.